Australian Pharmacy Stock of Abortion Pills Surges Nearly 50% Following Regulatory Relaxation in 2023
Australian pharmacies stocking the abortion medication MS-2 Step increased their inventory by nearly fifty percent following the relaxation of prescribing restrictions implemented in 2023, according to a study published in the medical journal JAMA Network Open on Thursday. The research indicates that deregulating access to the drug promotes safer and faster healthcare outcomes for patients seeking termination services.
The Therapeutic Goods Administration enacted changes in 2023 that allowed any general practitioner to prescribe the medication without prior additional training or registration. The requirement for pharmacists to be specifically registered to dispense the drug was also removed, alongside the easing of various administrative hurdles. Appropriately trained nurse practitioners and endorsed midwives were simultaneously made eligible prescribers under the new framework.
Researchers led by La Trobe University analyzed pharmacy ordering data from the two years preceding the policy shift against the two years following it. By mid-2025, the number of pharmacies stocking the medication had risen from 2,228 to 4,107. This expansion extended geographic reach significantly, with the number of postcodes containing at least one stocking pharmacy increasing from 915 to 1,292, covering nearly half of all Australian postcodes.
Regional accessibility saw marked improvement, with coverage rising from twenty-three percent to thirty-five percent of postcodes. In remote areas, the proportion of stocking pharmacies nearly doubled, moving from twelve point five percent to twenty-two percent. Prof Kristina Edvardsson from La Trobe University’s school of nursing and midwifery stated that these findings demonstrate that women requiring the medication can now access it closer to home.
Edvardsson emphasized that removing unnecessary travel reduces stress, particularly for disadvantaged women and those in rural or remote locations who may lack the means to travel long distances. She noted that local pickup options enable quicker care delivery. Other studies cited by Edvardsson confirm that improving access to MS-2 Step is safe and correlates with a decrease in the need for surgical abortions. She observed that medical abortion currently accounts for more than ninety percent of procedures in some European countries and suggested Australia is heading in a similar direction.
MS-2 Step, available under the Pharmaceutical Benefits Scheme, consists of mifepristone and misoprostol and can be used up to sixty-three days of gestation. While it was the only option during the study period, an additional drug named Arzestra, comprising the same active ingredients, was approved by the Therapeutic Goods Administration in February.
Dr Anna Noonan, a postdoctoral research fellow at the University of Technology Sydney, described the data as a critical signal for nations maintaining restrictive prescribing laws, such as the United States. She argued that pervasive barriers and overregulation hinder timely care and create extra work for healthcare providers who must proactively coordinate with pharmacies. Noonan concluded that encouraging a deregulated environment facilitates easier access, especially for individuals with fewer resources.
This report was produced in the Europe Brief News newsroom.
